Arcellx, Inc. (NASDAQ:ACLX) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. increased its holdings in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 141.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 156,094 shares of the company's stock after purchasing an additional 91,430 shares during the period. Federated Hermes Inc. owned approximately 0.29% of Arcellx worth $11,971,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Xponance Inc. grew its holdings in shares of Arcellx by 8.6% during the 4th quarter. Xponance Inc. now owns 3,088 shares of the company's stock worth $237,000 after acquiring an additional 244 shares during the period. KBC Group NV increased its stake in shares of Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after acquiring an additional 377 shares in the last quarter. Swiss National Bank boosted its stake in Arcellx by 0.8% during the fourth quarter. Swiss National Bank now owns 63,400 shares of the company's stock worth $4,862,000 after acquiring an additional 500 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Arcellx during the fourth quarter valued at approximately $41,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Arcellx by 9.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock worth $754,000 after purchasing an additional 858 shares in the last quarter. Institutional investors own 96.03% of the company's stock.

Insiders Place Their Bets

In other news, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $57.50, for a total transaction of $86,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rami Elghandour sold 38,300 shares of Arcellx stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total value of $2,375,366.00. Following the sale, the insider now directly owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. This trade represents a 20.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,455 shares of company stock worth $3,408,458. Company insiders own 6.24% of the company's stock.

Arcellx Stock Up 0.8 %

Shares of NASDAQ ACLX traded up $0.49 during trading on Tuesday, reaching $60.79. The company had a trading volume of 167,191 shares, compared to its average volume of 555,599. The stock has a market cap of $3.34 billion, a PE ratio of -85.53 and a beta of 0.33. The business's 50-day moving average is $65.27 and its 200 day moving average is $75.74. Arcellx, Inc. has a 12-month low of $47.88 and a 12-month high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The firm had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. On average, analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).